1.Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update.
Sheng Min WANG ; Changsu HAN ; Soo Jung LEE ; Tae Youn JUN ; Ashwin A PATKAR ; Prakash S MASAND ; Chi Un PAE
Chonnam Medical Journal 2019;55(1):73-73
The Acknowledgement was published incorrectly.
2.Paired Box Gene 8 (Pax8) Is also an Immunomarker of B-Cell Lineage Which Can Be Source of Diagnostic Pitfalls.
Chonnam Medical Journal 2019;55(1):70-72
No abstract available.
B-Lymphocytes*
3.Clinical Significance of the Interval Change of Plasma Neutrophil Gelatinase-Associated Lipocalin in Acute Kidney Injury and Acute Kidney Injury Superimposed on Chronic Kidney Disease.
Ha Yeon KIM ; Chang Seong KIM ; Eun Hui BAE ; Soo Wan KIM ; Seong Kwon MA
Chonnam Medical Journal 2019;55(1):68-69
No abstract available.
Acute Kidney Injury*
;
Lipocalins*
;
Neutrophils*
;
Plasma*
;
Renal Insufficiency, Chronic*
4.Successful Drug-Eluting Stent Overexpansion with Intravascular Ultrasound Guidance for Left Main Bifurcation Lesion Via Left Snuffbox Approach.
Yongcheol KIM ; Myung Ho JEONG ; Min Chul KIM ; Doo Sun SIM ; Young Joon HONG ; Ju Han KIM ; Youngkeun AHN
Chonnam Medical Journal 2019;55(1):66-67
No abstract available.
Drug-Eluting Stents*
;
Ultrasonography*
5.Bilateral Parapelvic Cyst Misdiagnosed as Hydronephrosis.
Hong Sang CHOI ; Chang Seong KIM ; Eun Hui BAE ; Seong Kwon MA ; Soo Wan KIM
Chonnam Medical Journal 2019;55(1):65-65
No abstract available.
Hydronephrosis*
6.Ball Valve Syndrome Caused by a Balloon-tipped Gastrostomy Tube.
Chonnam Medical Journal 2019;55(1):64-64
No abstract available.
Gastrostomy*
7.Spinal Extradural Meningeal Cyst: A Case Report.
Seul Kee LEE ; Jae Young KIM ; Ju Hwi KIM ; Bong Ju MOON ; Jung Kil LEE ; Soo Han KIM
Chonnam Medical Journal 2019;55(1):62-63
No abstract available.
8.Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis.
Hyung Ki JEONG ; Ki Hong LEE ; Hyung Wook PARK ; Nam Sik YOON ; Min Chul KIM ; Nuri LEE ; Ji Sung KIM ; Youngkeun AHN ; Myung Ho JEONG ; Jong Chun PARK ; Jeong Gwan CHO
Chonnam Medical Journal 2019;55(1):54-61
Rivaroxaban has emerged as a potential alternative to warfarin for the prevention of thromboembolism in patients with atrial fibrillation (AF). However, there has been concern for the risk of major bleeding, especially in Asian patients. We investigated the efficacy and safety of rivaroxaban compared to warfarin in Korean real world practice. A total of 2,208 consecutive non-valvular AF patients were divided into the Warfarin group (n=990) and the Rivaroxaban group (n=1218). Propensity matched 1-year clinical outcomes were compared (Warfarin, n=804; Rivaroxaban, n=804). The efficacy outcome was defined as stroke/systemic embolism (SE). The safety outcome was major bleeding. The primary net clinical benefit (NCB) was defined as the composite of stroke/SE, major bleeding, and all-cause mortality. Secondary, NCB was defined as the composite of stroke, SE, and major bleeding. Rivaroxaban had the similar efficacy in terms of thromboembolic event prevention [hazard ratio (HR) 0.69, 95% confidence interval (CI) 0.37–1.32, p=0.266] compared to warfarin. Rivaroxaban significantly lowered the risk of major bleeding [HR 0.41, 95% CI 0.22–0.76, p=0.004]. Primary NCB was significantly low in the rivaroxaban group [HR 0.54, 95% CI 0.36–0.81, p=0.003]. Secondary NCB was also low in the rivaroxaban group [HR 0.62, 95% CI 0.40–0.99, p=0.041]. Both rivaroxaban 15 mg and 20 mg groups had similar efficacy and significantly lower risks of major bleeding as well as primary and secondary NCB compared to the warfarin group. In patients with non-valvular AF, rivaroxaban had a similar efficacy to warfarin in Korean real world practice. However, rivaroxaban had better safety and net clinical outcomes compared to warfarin.
Asian Continental Ancestry Group
;
Atrial Fibrillation*
;
Cohort Studies*
;
Embolism
;
Hemorrhage
;
Humans
;
Mortality
;
Rivaroxaban*
;
Stroke
;
Thromboembolism
;
Warfarin*
9.Adherence to the GOLD Guideline in COPD Management of South Korea: Findings from KOCOSS Study 2011–2018.
Tae Ok KIM ; Hong Joon SHIN ; Yu Il KIM ; Chin Kook RHEE ; Won Yeon LEE ; Seong Yong LIM ; Seung Won RA ; Ki Suck JUNG ; Kwang Ha YOO ; Seoung Ju PARK ; Sung Chul LIM
Chonnam Medical Journal 2019;55(1):47-53
The guidelines for chronic obstructive pulmonary disease (COPD) treatment are important for the management of the disease. However, studies regarding the treatment adherence to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have been scarce in Korea. Therefore, to examine the adherence to the GOLD guidelines, we examined the patterns of prescribed medication in COPD patients from 2011 to 2018. Patients were classified as having been appropriately and inappropriately treated (overtreatment or undertreatment) for the GOLD group. Appropriate medical therapy was defined as using the first choice or alternative choice drug recommended in the GOLD guidelines. Inappropriate therapy was classified as overtreatment or undertreatment in accordance with the categorization in the GOLD guidelines. According to treatment of 2011 GOLD guidelines, there was inappropriate treatment in 52.3% in group A, 47.3% in group B, 56.3% in group C, and 17.8% in group D. According to treatment of 2017 GOLD guidelines, there was inappropriate treatment in 66.7% in group A, 45.3% in group B, 14.3% in group C, and 24.0% in group D. The common type of inappropriate COPD treatment is overtreatment, with inhaled corticosteroid (ICS) containing regimens. In conclusions, adherence to the GOLD guideline by the pulmonologist in clinical practice is still low in Korea. Therefore, we need better strategies to both optimize the use of the guidelines and adhere to the guidelines as well.
Humans
;
Korea*
;
Lung Diseases
;
Medical Overuse
;
Pulmonary Disease, Chronic Obstructive*
10.Predictors of In-Hospital Mortality in Korean Patients with Acute Myocardial Infarction.
Hae Young YANG ; Min Joo AHN ; Myung Ho JEONG ; Youngkeun AHN ; Young Jo KIM ; Myeong Chan CHO ; Chong Jin KIM
Chonnam Medical Journal 2019;55(1):40-46
Acute myocardial infarction (AMI) is a fatal cardiovascular disease, and mortality is relatively high; therefore, integrated assessment is necessary for its management. There are several risk predictive models, but treatment trends have changed due to newly introduced medications and the universal use of percutaneous coronary intervention (PCI). The author aimed to find out predictive factors of in-hospital mortality in Korean patients with AMI. A group of 13,104 patients with AMI enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH) registry were divided into two groups. One was a derivation group for evaluating mortality prediction; the other was a validation group for the application of risk prediction. In-hospital mortality was 4.2% (n=552). With hierarchical and stepwise multivariate analyses, nine factors were shown to predict in-hospital mortality for Korean patients with AMI. These were 1) being over 65 years of age, 2) high Killip class over II, 3) hyperglycemia over 180 mg/dl, 4) tachycardia over 100/min, 5) serum creatinine over 1.5 mg/dl, 6) atypical chest pain, 7) low systolic blood pressure under 90 mmHg, 8) low Thrombolysis In Myocardial Infarction (TIMI) flow (TIMI 0-II) before PCI and 9) low TIMI flow (TIMI 0-II) after PCI. The validation group showed a predictive power of 88.3%. Old age, high Killip class, hyperglycemia, tachycardia, renal dysfunction, atypical chest pain, low systolic blood pressure, and low TIMI flow are important risk factors of in-hospital mortality in Korean patients with AMI.
Blood Pressure
;
Cardiovascular Diseases
;
Chest Pain
;
Creatinine
;
Hospital Mortality*
;
Humans
;
Hyperglycemia
;
Korea
;
Mortality
;
Multivariate Analysis
;
Myocardial Infarction*
;
Percutaneous Coronary Intervention
;
Prognosis
;
Risk Factors
;
Tachycardia